Article

Comparative physicochemical and structural characterisation studies establish high Biosimilarity between BGL-ASP and Reference Insulin Aspart

2023-10-24

Abstract excerpt

Biosimilar insulin analogues are increasing market access for diabetic patients globally. Scientific establishment of biosimilarity is cornerstone of this key change in the medical landscape. BGL-ASP is a biosimilar insulin aspart developed by BioGenomics Limited, India. BioGenomics has considered a stepwise approach in generating the totality of evidence required to establish similarity with reference product. In...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: aab6aa22-4d57-5b88-942a-20620d484dfe
DOI: 10.21203/rs.3.rs-3461609/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Comparative physicochemical and structural characterisation studies establish high Biosimilarity between BGL-ASP and Reference Insulin AspartDOI 10.21203/rs.3.rs-3461609/v1Read

Molecular variants and derivatives of insulin for improved glycemic control in diabetes.Semantic proximity Read

The road to the first, fully active and more stable human insulin variant with an additional disulfide bond.Semantic proximity Read

Large Scale Purification and Characterization of A21 Deamidated Variant-Most Prominent Post Translational Modification (PTM) for Insulins Which Is Widely Observed in Insulins Pharmaceutical ManufacturingSemantic proximity Read

In vivo challenges of anti-diabetic peptide therapeutics: Gastrointestinal stability, toxicity and allergenicitySemantic proximity Read

Recombinant DNA Technology in the Treatment of Diabetes: Insulin AnalogsSemantic proximity Read

Se-Glargine I. Chemical Synthesis of a Basal Insulin Analog Stabilized by an Internal Diselenide BridgeSemantic proximity Read

Se-Glargine II. Native Function of a Basal Insulin Analog Stabilized by an Internal Diselenide BridgeSemantic proximity Read

Clinical Research out of Insulin Glargine U300 basal bolus therapy and Insulin Degludec/Aspart Co-Formulation in Type 2 Diabetes Mellitus: A Real World ExperienceSemantic proximity Read

Biological and biosimilar medicinal products: safety and efficacySemantic proximity Read

Identification of multiple serine to asparagine sequence variation sites in an intended copy product of LUCENTIS® by mass spectrometry.Semantic proximity Read

Identification, characterization and control of a sequence variant in monoclonal antibody drug product: a case study.Semantic proximity Read